L3VLUP
ProSign in

JNJ · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

JNJLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • JNJ
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterJNJLLY
Q3 202030 holders, $26.2bn33 holders, $14.1bn
Q4 202032 holders, $26.6bn29 holders, $17.3bn
Q1 202131 holders, $25.3bn24 holders, $23.0bn
Q2 202137 holders, $25.6bn24 holders, $27.8bn
Q3 202140 holders, $24.1bn31 holders, $29.9bn
Q4 202133 holders, $25.2bn31 holders, $34.7bn
Q1 202235 holders, $28.2bn24 holders, $35.3bn
Q2 202233 holders, $26.9bn33 holders, $42.7bn
Q3 202236 holders, $25.4bn31 holders, $43.4bn
Q4 202235 holders, $27.6bn31 holders, $46.6bn
Q1 202342 holders, $24.5bn33 holders, $44.3bn
Q2 202338 holders, $25.0bn37 holders, $59.6bn
Q3 202337 holders, $18.9bn44 holders, $67.6bn
Q4 202331 holders, $19.0bn45 holders, $73.6bn
Q1 202432 holders, $19.7bn41 holders, $95.3bn
Q2 202435 holders, $20.4bn43 holders, $110bn
Q3 202428 holders, $22.3bn45 holders, $107bn
Q4 202437 holders, $20.4bn46 holders, $93.9bn
Q1 202532 holders, $20.5bn42 holders, $98.4bn
Q2 202531 holders, $18.4bn43 holders, $93.2bn
Q3 202532 holders, $23.7bn39 holders, $86.7bn
Q4 202529 holders, $27.8bn41 holders, $123bn
Q1 202634 holders, $35.6bn39 holders, $106bn
Q2 202633 holders, $39.1bn44 holders, $132bn
JNJ

Johnson & Johnson

Holders
34
Reported value
$35.6bn
Buyers
21
Sellers
18

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 47 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only JNJ (8)

Balyasny Asset Management LLC, Farallon Capital Management LLC, Freestone Grove Partners LP, Markel Group Inc, MFS Investment Management, Rokos Capital Management LLP, Verition Fund Management LLC, Winton Group Ltd

Only LLY (13)

ARK Investment Management LLC, Artisan Partners LP, Caxton Associates LLP, ExodusPoint Capital Management LP, Harris Associates LP, Holocene Advisors LP, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Two Sigma Investments LP, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →